Sarepta Therapeutics (STU:AB3A) Valuation Rank


STU:AB3A Sarepta Therapeutics Inc STU:AB3A
54 GF Score
Price €16.54
GF Value €115.29
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sarepta Therapeutics Valuation Rank Related Terms

STU:AB3A
54GF Score
Sarepta Therapeutics Inc STU:AB3A
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sarepta Therapeutics (STU:AB3A) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of €16.54 is trading 85.7% below its estimated GF Value™ of €115.29. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for STU:AB3A:

  • Valuation Rank:
  • GF Value™: €115.29 vs. price of €16.54 (85.7% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the STU:AB3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
54GF Score

Get the complete analysis for STU:AB3A

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.54
Price
€115.29
GF Value